Fate Therapeutics, Inc.
FATEHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. With a market capitalization of $331.0M, it sits in small-cap territory. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Market Cap
$331.0M
Beta
2.14
P/E (TTM)
—
P/E (Fwd)
-3.07
EPS (TTM)
$-1.09
EPS (Fwd)
$-0.92
ROE
-55.5%
ROA
-25.3%
Cash
$174.8M
Total Debt
$76.8M
Free CF
-$50.1M
52W Change
118.5%
Annual Financials
Cash vs Debt
Fate Therapeutics, Inc. holds $174.8M in cash against $76.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$50.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $96.3M (2022) to $6.6M (2025), a 93% decline worth watching.
With a beta above 1.5, FATE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, FATE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing FATE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.